

<b>Evidence gap identifier</b>	EBAR 1
<b>Brief title</b>	Cost of antimicrobial-resistant pathogen outbreaks in public acute hospitals
<b>Report</b>	<u>Economic Burden of Antimicrobial Resistance (AMR)</u>
<b>Date identified</b>	09/11/2020
<b>Identified by</b>	CICER
<b>Supported by</b>	Rapid review
<b>Population</b>	Patients involved in an antimicrobial resistant pathogen outbreak
<b>Intervention</b>	Interest: methodology used to estimate costs; costs considered (including resource use)
<b>Comparator</b>	N/A
<b>Outcome(s)</b>	Author-reported costs (i.e., numerical cost estimates)
<b>Setting</b>	Acute public hospital (at population-level)
<b>Study design</b>	Economic costing (nationally representative survey and expert consensus)
<b>Further information</b>	Relatively little evidence exists on the cost of antimicrobial resistant pathogen outbreaks in public acute hospitals. Further research such as nationally representative surveys and expert consensus to elicit resources used and associated costs, including opportunity costs, relating to outbreaks of antimicrobial-resistant pathogens in public acute hospitals at a population level, are needed.